Eugen Stermetz

Swisscom (Schweiz) AG engages in the provision of telecommunications, broadcasting, and information technology services. It also specializes in the marketing of products for computer systems, including the design, development, and licensing of software. The company was founded on December 9, 1997 and is headquartered in Bern, Switzerland.

Fastweb SpA engages in the provision of solutions for internet connectivity. The firm offers a wide range of voice and data services, fixed communication, and mobile to households and businesses. It also constructs fiber optic network infrastructure and adopts internet protocol for voice, data, and video transmission. The company was founded by Silvio Scaglia in September 1999 and is headquartered in Milan, Italy.

SVOX AG develops speech, voice and language output solutions and related equipment. The company was founded by Volker P. Jantzen, Alexander E. Fries and Bettina Hein in April 2000 and is headquartered in Zurich, Switzerland.

F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria.

Part of BCG Holding Group SCS, Boston Consulting Group Service GmbH is a German company that provides management consulting services. The private company is based in Munich, Germany.

FIBREX Medical Inc. is a development stage bio-pharmaceutical company. Its operational affiliate FIBREX Medical Research & Development GmbH was established in Vienna in February 2001. The company was founded to convert high impact scientific discovery into pharmaceutical products for important diseases. The company aims to become a leader in the development and commercialization of pharmaceuticals targeting fundamental mechanisms of inflammation and tissue injury. While inflammation is highly desirable to defend the organism against foreign particles and infections, it can become harmful and destructive if it runs unchecked. Inflammation-based tissue injury is well known as a major component in the pathogenesis and progression of important diseases such as myocardial infarction, septic and hemorrhagic shock, graft rejection, or rheumatoid arthritis. In addition, endothelial dysfunction in inflamed tissues leads to capillary leak and deleterious edema formation, aggravating organ dysfunction.